Ph 3 trial of Anbenitamab (KN026) + Docetaxel For Injection (Albumin-Bound) (HB1801) For 1L HER2+ve Advanced Breast Cancer Meets Primary Endpoint
Phase III clinical study (Study Protocol No.: KN026-003) of Anbenitamab (‘‘KN026’’), co-developed by Shanghai JMT-BIO Technology Co., Ltd. (‘‘JMT-BIO’’), a subsidiary of the Company, and Jiangsu Alphamab Oncology Co., Ltd., in combination with the Group’s self-developed Docetaxel for Injection (Albumin-bound) (‘‘HB1801’’) for the first-line treatment of HER2-positive advanced breast cancer has successfully met the pre-specified primary endpoint of progression-free survival (‘‘PFS’’) as assessed by the Independent Data Monitoring Committee (the ‘‘IDMC’’), yielding results that are both statistically significant and clinically meaningful, with a favourable safety profile.
Share:
More News
“The positive outcome of our pre-IND interactions with the FDA reinforces the development pathway for MaaT034 and supports its continued advancement toward the clinic. It also represents an important step in MaaT Pharma’s expansion into immuno-oncology, highlighting the broader potential of our first in class co-cultivated microbiome donor-independent platform across
“Patients with metastatic RAS G12D non-squamous NSCLC, occurring in approximately 4% of cases, represent an underserved population, with no approved targeted treatment options. Initial clinical data evaluating zoldonrasib in combination with standard of care pembrolizumab and platinum doublet chemotherapy in patients with previously untreated metastatic RAS G12D non-squamous NSCLC showed
“At Georgiamune, we are focused on uncovering novel mechanisms that control immune-cell function and translating that biology into first-in-class medicines across autoimmune disease and oncology,” said Samir N. Khleif, M.D., Founder and Chief Executive Officer of Georgiamune. “GIM-621 is one of multiple programs to emerge from that work, alongside three
“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000